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Laboratory mice frequently are anesthetized by subcutaneous 
or intraperitoneal injection of hypnotic, analgesic, and muscle-
relaxing agents.35 Although easy, practical and cost-effective, 
this method has its drawbacks. After injection of relatively 
long-acting drugs through the subcutaneous or intraperitoneal 
route, the course and depth of anesthesia is nearly uncontrol-
lable once the initial dose has been administered. In addition, 
due to the considerable variability in dose requirements for 
mice of different age, strain, sex, and other specifics (for ex-
ample, circadian rhythm, sociophysiologic conditions), the 
margin between reaching a state of anesthesia sufficiently deep 
to provide surgical tolerance and a lethal outcome is usually 
narrow.1 Moreover, most injection anesthesia protocols induce 
a prolonged recovery period accompanied by hypothermia and 
compromised physiologic function.
Such problems rarely are encountered with inhalation an-
esthesia, because this method has a short recovery phase and 
accommodates control of the duration and depth of anesthesia, 
including expeditious adjustment of the dosage of inhalation 
anesthetics tailored to the requirements of the individual ani-
mal. Therefore, in terms of survival rate, inhalation anesthesia 
generally is suggested to be safe in mice. However, negative 
effects on the cardiovascular system combined with depres-
sion of respiration are well-known side effects of halogenated 
volatile anesthetics.18,19,46 This situation, coupled with the fact 
that the analgesia provided by monoanesthesia with volatile 
anesthetics is still controversial,9,15 justifies a continued search 
for improvement.
By taking advantage of the well-known synergistic and 
additive interactions between injectable drugs (analgesics or 
sedatives) and volatile anesthetics, the dosages of each compo-
nent can be decreased (relative to its use as a sole agent) while 
inducing general anesthesia of sufficient depth with fewer side 
effects.16,20,32 This approach, sometimes referred to as ‘balanced’ 
or ‘modular’ anesthesia,49 is used widely in human and veteri-
nary medicine—but only recently has it has begun to be used in 
mice. Therefore, in the present study, 2 protocols of combined 
injection and inhalant anesthesia in laboratory mice were es-
tablished and compared with a standard protocol of inhalant 
monoanesthesia with a commonly used volatile anesthetic.
Isoflurane and sevoflurane are the 2 of the volatile anesthet-
ics most widely used in human and veterinary anesthesia. We 
decided to use sevoflurane to provide rapid induction and 
recovery. Because we considered that volatile anesthetics offer 
suboptimal analgesia, we focused on injectable agents that could 
provide sufficient analgesia to complement inhalant anesthesia. 
Ketamine is known for its ability to cause profound analgesia, 
which can occur even at subhypnotic dosages—particularly if 
the S(+)-enantiomer of ketamine is adminstered.36 Therefore, we 
chose S-ketamine for injection in one protocol. We calculated 
the dosage based on literature reports,17,34,36,37 with the aim of 
minimizing side effects such as catalepsy, slight respiratory 
depression, and stimulation of locomotor activity (restlessness) 
while inducing analgesia and taking advantage of the hypnotic 
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access to sterilized drinking water provided in a water bottle. 
The 12:12-h light:dark cycle in the room was established with 
artificial light (approximately 40 lx in the cage; lights on, 0300 
to 1500). The temperature was 21 ± 1 °C, with a relative humid-
ity of 50% ± 5% and 15 complete changes of HEPA-filtered air 
hourly. To avoid interfering influences, all necessary husbandry 
and management procedures were completed in the room at 
least a d before the start of an experiment or data recording, and 
disturbances (for example, visitors or unrelated experimental 
procedures) were not allowed. The animal room was insulated 
to exclude electronic noise.
The study and all procedures and protocols were approved 
by the Cantonal Veterinary Office (Zurich, Switzerland) under 
license number 111/2007. Housing and experimental proce-
dures were in accordance with Swiss animal protection law 
and conformed to the European Convention for the protection 
of vertebrate animals used for experimental and other scientific 
purposes (Council of Europe nr.123 Strasbourg 1985).10 Housing 
and experimental procedures also were in accordance with the 
Guide for the Care and Use of Laboratory Animals22 and conformed 
to the AALAS position statement on the humane care and use 
of laboratory animals.
Transmitter implantation. Prior to the experiments, at age 
10 wk, 26 mice were instrumented with telemetric transmit-
ters (TA10ETA-F20, Data Sciences International, St Paul, MN) 
to measure heart rate, core body temperature, and locomotor 
activity in freely moving mice.2,44 Briefly, mice were anesthe-
tized with sevoflurane (Sevorane, Abbott, Baar, Switzerland), 
and the transmitter body was implanted in the abdomen under 
aseptic conditions. One wire-loop electrode was fixed with silk 
sutures (6-0 Perma-Handseide, Ethicon, Norderstedt, Germany) 
between the muscles located to the right of the trachea, and 
the other loop lead was sutured to the xiphoid process. Mus-
cle layers and skin were closed with resorbable sutures (6-0 
Vicryl, Ethicon). Postoperative pain was treated with flunixine 
(5 mg/kg SC twice daily; Biokema Flunixine, Biokema SA, 
Crissier-Lausanne, Switzerland) for 4 d.38 After transmitter 
implantation, mice were allowed to recover for 6 wk before 
the first experiment.
Experimental setting. All experiments were conducted when 
the mice were 16 to 36 wk of age, with body weights ranging 
from 25 to 30 g. To avoid any influence of circadian rhythm, 
all experiments and weighing procedures were done between 
1500 and 1800. The study was designed for the experiments and 
anesthesia to be performed at the beginning of the dark phase for 
these mice. Anesthesia was performed in a separate operating 
area within the animal room to avoid transportation of the mice 
and to ensure stable conditions of humidity, air pressure, and 
room temperature and sufficient removal of gases and smells 
through the ventilation system.
The method of delivering inhalation anesthesia was modified 
slightly from that described elsewhere.6 Briefly, sevoflurane was 
provided by using a commercially available rodent inhalation 
anesthesia apparatus (Provet, Lyssach, Switzerland), which 
was equipped with a sevoflurane vaporizer (Ohmeda Sevotec 
5, Abbott, Baar, Switzerland) and a pump-driven filter system 
to eliminate waste anesthetic gas. As carrier gas, pressurized air 
was used at a flow rate of 600 mL/min. The anesthetic gas was 
introduced into the induction chamber or nose mask (Figure 1).
Premedications. As injectable drugs, we used fentanyl (0.04 
mg/kg SC; Kantonsapotheke Zurich, Zurich, Switzerland) 
mixed with midazolam (4 mg/kg SC; Dormicum, Roche Pharma 
Schweiz AG, Reinach, Switzerland) in one protocol and S-
ketamine (30 mg/kg SC; Keta-S, Graeub AG, Bern, Switzerland) 
and cardiovascular stimulatory effects of ketamine.17,30 Our 
second approach to combining inhalation anesthesia with inject-
able agents in mice was based on drugs that are used widely in 
human medicine, namely fentanyl and midazolam. Midazolam, 
which often is applied as premedication to anesthesia, belongs 
to the benzodiazepines, which typically induce sedation, 
anxiolysis, and muscle relaxation.28 Antinociceptive effects of 
midazolam have been reported in mice8 and rats.5 In humans, 
benzodiazepines frequently are administered with opioids to 
improve pain relief. Therefore, we combined midazolam with 
fentanyl—a potent synthetic opioid analgesic. Among the typi-
cal side effects of opioids,26 sedation, hypothermia, respiratory 
depression, and hypercapnia could be of relevance for the use of 
fentanyl during anesthesia in mice. Although opioids can cause 
bradycardia, vasodilation, and hypotension, they have mostly 
only mild effects on cardiovascular function. In addition, their 
effects on the genitourinary system and gastrointestinal tract26 
(for example, constipation) are suggested to be tolerable side 
effects, which may be of only minor relevance for establishing 
an anesthesia protocol in mice. Fentanyl often is administered 
as an intravenous constant-rate infusion in the context of 
anesthesia in humans,48 but this technique is complex and dif-
ficult to manage in mice. Therefore, we attempted to achieve 
preemptive analgesia with subcutaneous injection of fentanyl 
with midazolam as premedication, with dosages selected on 
the basis of anecdotal evidence, clinical experience, and hints 
from the literature.47
To compare the 3 anesthesia protocols, 50 min of sevoflurane 
inhalant anesthesia was conducted either alone (S) or with 
subcutaneous injection of S-ketamine (KS) or a mixture of fen-
tanyl and midazolam (FMS). Injections were administered as 
premedication, and their effects on behavior during induction of 
anesthesia and on the sevoflurane concentration required were 
noted. During anesthesia, heart rate, core body temperature, 
respiratory rate, arterial blood gases, and arterial pH were moni-
tored. The long-term effect of the 3 protocols on recovery from 
anesthesia was investigated through telemetric measurements 
of heart rate, core body temperature, and locomotor activity for 
3 d after anesthesia.
Materials and Methods
Animals and housing conditions. Female C57BL/6J mice (n = 
98; age, 6 wk) were obtained from our inhouse breeding colony. 
The 72 mice used for determination of minimal alveolar con-
centrations were later euthanized to obtain arterial blood for 
measuring acid–base balance and blood gas concentrations. The 
remaining 26 mice were implanted with telemetric transmitters 
prior to the experiments to allow measurement of heart rate, 
core body temperature, and locomotor activity. The mice were 
free of all viral, bacterial, and parasitic pathogens listed in the 
FELASA recommendations.33 Health status was monitored by 
a sentinel program throughout the experiments.
Mice generally were housed in pairs; each transmitter-im-
planted mouse was housed with a nonimplanted companion of 
the same strain, sex, and age. Mice were kept in Eurostandard 
type III open-top plastic cages (425 mm × 266 mm × 155 mm, 
floor area 820 cm2, Tecniplast, Indulab, Gams, Switzerland) 
with autoclaved aspen bedding (80 to 90 g per cage; LTE E-001 
Abedd, Indulab). Autoclaved hay (8 to 12 g per cage) and 2 
cotton nesting pads (each 5 × 5 cm; Nestlets, Indulab) were 
provided as nesting materials. A standard cardboard house 
(Ketchum Manufacturing, Brockville, Canada) served as a 
shelter. Mice were fed a pelleted mouse diet (3431, Provimi 
Kliba, Kaiseraugst, Switzerland) ad libitum and had unrestricted 
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The bracketed study design41 was adapted to our anesthesia pro-
tocols to measure minimal alveolar concentration at a defined 
time point of anesthesia, that is, at 12 min after inducing inha-
lant anesthesia (equivalent to 17 to 19 min after subcutaneous 
injection of premedication). Thus, after inducing sevoflurane 
anesthesia in the induction chamber (Figure 1 A) for 1.5 min 
at a maximal concentration of 8% sevoflurane, the mouse was 
taken out of the chamber and placed in dorsal recumbency 
on a warmed mat. Anesthetic gas then was applied at the test 
concentration by using a nose mask, with the mouse breathing 
spontaneously (Figure 1 B). After an equilibration time of 10 min, 
3 noxious stimuli were applied sequentially: pinching of the 
tail (tail pinch reflex), interdigital webbing (pedal withdrawal 
reflex), and abdominal skin (abdominal skin pinch reflex). 
All stimuli were induced by the same investigator by using 
in another. All drugs were dissolved in PBS immediately before 
injection in such a manner that dosing could be achieved by 
application of an injection volume of 2 μL/kg body weight. 
Injections were provided as premedication, that is, 5 to 7 min 
before sevoflurane anesthesia was induced.
Determination of minimal alveolar concentration. Sevoflurane 
inhalation anesthesia was standardized by establishing minimum 
alveolar concentrations during sevoflurane monoanesthesia and 
after the premedications described earlier. To this end, we anes-
thetized 72 nontransmitter-implanted mice 2 to 4 times each; care 
was taken that mice had a break of at least 2 wk between tests.
Minimal alveolar concentration was determined according 
to commonly accepted procedures used in mice.6,7,14,23,42,43 For 
each protocol, 4 consecutive sevoflurane concentrations differ-
ing by 0.25% were tested; 25 mice were tested per concentration. 
Figure 1. (A) Chamber for induction of sevoflurane inhalation anesthesia. (B) Nose mask for maintaining sevoflurane anesthesia. The mask was 
equipped with a latex membrane, which had a hole in the center that fit around the nose of each mouse, with the dual purpose of preventing 
both withdrawal of environmental air into the nose mask and leakage of anesthetic gas from it.
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For analysis of long-term postanesthetic effects, we took into 
account that values vary greatly during a 24-h cycle because 
mice are active mainly at night. Therefore, the means of the 
telemetric values for each mouse were calculated separately 
for the 12-h dark (night) and 12-h light (day) phases. A mouse’s 
baseline values were established by calculating means from the 
3 d prior to anesthesia. For each day after anesthesia, a mouse’s 
baseline value was subtracted individually from its daytime and 
nighttime means; the differences are reported as delta (Δ) values.
Changes in body weight. Body weight in transmitter-implant-
ed mice was monitored for 3 d before and 3 d after anesthesia. 
Weights were obtained by using a precision balance (PR 2003 
Delta Range, Mettler-Toledo AG, Greifensee, Switzerland) 
that specifically was adjusted for use with moving animals. 
Body weights were corrected to account for the weight of the 
transmitter (3.6 g). Mean baseline weight (from 3 consecutive 
daily measurements prior to the experiment) was calculated for 
each mouse and compared with that recorded on each of the 
3 d after the experiment.
Acid–base balance and blood gas concentration. At 3 to 
4 wk after determination of minimal alveolar concentration 
determination, arterial blood was collected from the same 72 
nonimplanted mice to assess acute effects of anesthesia on 
respiration and acid–base balance. Arterial blood was obtained 
after 10, 30, and 50 min of anesthesia from 8 mice per anesthetic 
protocol and time point.
Blood sampling and analyses were carried out as described 
previously.1,6 Briefly, the anterior neck was incised, the right 
common carotid artery was dissected out, a small hole in the 
artery was created by using fine-blade scissors, and arterial 
blood was collected in a heparinized syringe. Acid–base bal-
ance (pH), pCO2 (mm Hg), and pO2 (mm Hg) were determined 
immediately by using a blood-gas analyzer (Compact 3, AVL 
List, Graz, Austria). These mice died immediately due to the 
blunt forceps with a spacer between its arms to allow uniform 
application of pressure. Any motor response (for example, 
movement of the tail or an extremity, head jerking) to one or 
more of the 3 noxious stimuli was judged as purposeful move-
ment, indicating that sevoflurane at the concentration applied 
did not induce anesthesia in the mouse evaluated. After testing 
the response to the 3 noxious stimuli (that is, after 12 to 13 min 
of inhalant anesthesia), administration of the anesthetic gas 
ceased, and the mouse was allowed to recover. By using the 
responses to the noxious stimuli, the mouse’s minimal alveolar 
concentration was calculated as the average of the 2 partial 
pressures bracketing the positive response (that is, purposeful 
movement) or lack of response in the animal.
Anesthesia experiments. Mice were allocated randomly to 1 
of 3 anesthesia protocols. The 3 protocols consisted of fentanyl 
(0.04 mg/kg) and midazolam (4 mg/kg) as premedication and 
3.3% sevoflurane (FMS); S-ketamine (30 mg/kg) as premedication 
and 5% sevoflurane (KS); and 5% sevoflurane as monoanesthesia 
(S). After premedication in the FMS and KS protocols, the mice 
were examined for 5 to 7 min in their home cage for behavioral 
aberrations. Inhalant anesthesia then was induced by placing 
each mouse in a clear induction chamber (8 × 8 × 8 cm; volume, 
512 mL) into which 8% sevoflurane (Sevorane, Abbott, Baar, 
Switzerland) was introduced. The mouse’s behavior in the 
induction chamber and the time point at which it became im-
mobile were observed and noted. After 1.5 min, the mouse was 
transferred rapidly to the nose mask, through which anesthesia 
was maintained with sevoflurane. Mice breathed spontaneously 
while lying in dorsal recumbency on a water-filled warming mat 
(Gaymar, TP500, Orchard Park, NY) set at 39 °C ± 1 °C.
Tail pinch, pedal withdrawal, and abdominal skin pinch re-
flexes each were tested at 5-min intervals. All reflex tests were 
induced by the same investigator by using blunt forceps with 
a spacer between its arms to allow uniform application of pres-
sure. The reflex tests were registered as positive or negative (that 
is, whether any motor response was present or not).
Respiratory rate was counted from the movement of the 
thorax wall and recorded at 5-min intervals. During anesthesia, 
mice were observed for any abnormality in their respiratory 
rhythm. In addition, heart rhythm alterations were monitored 
by using real-time telemetric electrocardiograms.
Anesthesia was stopped after 50 min by removing the nose 
from the mask and letting the mouse breathe room air. Mice were 
left on the warming mat and allowed to recover from anesthesia 
for 10 min before being placed back in their home cages.
Telemetric data acquisition and analysis. Telemetric data 
were recorded from 8 mice per anesthetic protocol by using 
the Dataquest LabPRO program (Data Sciences International). 
Data collection was initiated by switching on the transmitter by 
using a magnet. Data acquisition started 3 d before anesthesia 
and continued for 3 d after anesthesia.
To estimate the acute effects of anesthesia (that is, after pre-
medication and during anesthesia), heart rate and core body 
temperature were recorded for 4 s every 15 s (4 data points of 
4 s per minute). From these data, mean values of heart rate and 
core body temperature were calculated for each minute for each 
mouse. Baseline values represent means from 1500 to 1800 (that 
is, the same time frame during which anesthesia occurred) dur-
ing the 3 d prior to the experiment.
To establish baseline values (3 d before anesthesia) and to 
investigate postanesthetic effects (3 d after anesthesia), heart rate 
was measured for 30 s every 5 min, and core body temperature 
was measured for 10 s every 5 min. Locomotor activity was 
recorded continuously and stored at 5-min intervals.
Figure 2. (A) Mean (n = 50 mice; bar, 1 SD) minimum alveolar concen-
trations for sevoflurane in adult C57BL/6J female mice. The gas-saving 
effect is evident from the decrease in minimum alveolar concentration 
seen after fentanyl–midazolam premedication with sevoflurane (FMS) 
compared with S-ketamine premedication with sevoflurane (KS) and 
sevoflurane alone (S). *, P ≤ 0.05 between values. (B) The mean time 
(n = 8 mice; bar, 1 SD) required until immobilization after mice were 
placed in the sevoflurane-filled induction chamber differed between 
all protocols. *, P ≤ 0.05 between values.
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The time until immobilization differed among all 3 protocols. 
The shortest time was associated with the FMS protocol and the 
longest with sevoflurane monoanesthesia (FMS compared with 
S, P = 0.0005; FMS compared with KS, P = 0.0005; KS compared 
with S, P = 0.004; Figure 2 B).
Effects during anesthesia. During anesthesia, none of the mice 
showed any motor response to testing of the pedal withdrawal 
reflex, tail pinch, or abdominal skin pinch.
During the 50-min anesthesia period in all 3 protocols, heart 
rate and core body temperature remained within the general 
physiologic boundaries for this species (350 to 800 bpm, 35 
to 38 °C; Figure 3). Heart rate was 446 ± 51 bpm during FMS 
anesthesia, 470 ± 59 bpm during KS anesthesia, and 519 ± 
60 bpm during sevoflurane monoanesthesia. Compared with 
the mean baseline heart rate at the corresponding time of day 
(525 ± 80 bpm), the decreases in heart rate during FMS (P = 
0.001) and KS (P = 0.030) were significant.
Compared with the baseline core body temperature at the 
same time of day (36.8 ± 0.7 °C), core body temperature was 
decreased significantly during FMS (35.4 ± 0.6 °C; P = 0.0005) 
and KS (35.4 ± 0.4 °C; P = 0.0005) anesthesia. Core body tem-
perature showed a tread toward a decrease during sevoflurane 
monoanesthesia (36.1 ± 0.7 °C; P = 0.058).
During all 3 protocols, the respiratory rate declined imme-
diately after the onset of sevoflurane anesthesia and remained 
markedly depressed during the 50-min anesthesia session 
compared with baseline respiration in resting mice at the 
same time of day (150 ± 10 breaths per minute; Figure 3). The 
respiratory rate during anesthesia was 68.5 ± 7.7 breaths per 
minute for FMS, 48.8 ± 5.4 breaths per minute for KS, and 44 ± 
5.1 breaths per minute for sevoflurane monoanesthesia. After 
10, 30 and 50 min of anesthesia in all 3 protocols, blood gas and 
pH measurements of arterial blood showed prominent acidosis, 
hypercapnia, and hypoxia, with values markedly exceeding the 
physiologic range (Figure 4).
During anesthesia with KS, all mice displayed cardiac ar-
rhythmia and episodes of apnea followed by tachypnea. None 
of these events occurred during either of the other 2 protocols. 
One transmitter-implanted mouse died at 15 min into KS an-
esthesia and was replaced.
Mice began showing increasing respiratory rate and muscle 
rigor within 1 min after sevoflurane was discontinued. In all 3 
protocols, the mice had turned to ventral recumbency and were 
able to move within approximately 2 min after sevoflurane 
withdrawal.
Effects during the first 3 d after anesthesia. Compared with 
baseline values, telemetric measurements revealed a significant 
(P = 0.0005) increase in heart rate during the first 12 h after 
anesthesia in all 3 protocols (Figure 5). Comparing between 
protocols, the increase in heart rate after sevoflurane monoan-
esthesia was significantly (P = 0.0005) higher than that after FMS 
anesthesia, whereas heart rate after KS anesthesia did not differ 
significantly from that in the other 2 protocols.
subsequent rapid loss of blood under anesthesia. Reference val-
ues of pH, pCO2, and pO2 for comparison had been established 
by using arterial blood from 20 HanIbm:NMRI mice that were 
similar in age to those in the current study.1
Statistical analysis. All data are presented as mean ± 1 SD. 
Statistical analysis (version 17.0, SPSS for Windows, SPSS, 
Chicago, IL) was done to validate the results. All data were tested 
for normal distribution and homogeneity of variance and met 
the necessary assumptions for parametric analyses. One-way 
ANOVA was performed to compare group means of minimal 
alveolar concentrations and time until immobilization as well as 
heart rate, core body temperature, and locomotor activity at each 
of the first 3 d after anesthesia. Post hoc analysis with Bonferroni 
tests was done to identify significant differences between groups. 
For comparison of baseline values with corresponding experi-
mental group means of heart rate, core body temperature, and 
locomotor activity during and at each of the 3 d after anesthesia, 
a dependent t test for paired samples was used. P values less than 
or equal to 0.05 were considered significant.
Results
Minimal alveolar concentration. The minimal alveolar con-
centration (mean ± 1 SD) for sevoflurane monoanesthesia and 
with premedication using S-ketamine in adult female C57BL/6J 
mice was 3.3% ± 0.18% (Figure 2 A). Premedication with fenta-
nyl–midazolam significantly (P = 0.0005) decreased the mean 
minimal alveolar concentration for sevoflurane to 2.2% ± 0.27% 
compared with that for the other 2 protocols. This decrease 
represents a gas savings of 33%.
We considered that providing sevoflurane at 1.5 times 
the minimal alveolar concentration would prevent mice 
from responding to noxious stimulation (that is, surgical 
tolerance is achieved). Therefore all subsequent anesthesia 
experiments were conducted by using 3.3% sevoflurane after 
fentanyl–midazolam premedication but by using 5% sevoflu-
rane after S-ketamine premedication and during sevoflurane 
monoanesthesia.
Induction of anesthesia. Approximately 2 min (107.5 ±18.3 s) 
after injection with fentanyl–midazolam, all mice showed signs 
of sedation (for example, absence of locomotion and stationary 
activity, sleep-like posture). Approximately 5 min (306 ± 55.8 s) 
after injection with S-ketamine, all mice exhibited symptoms of 
tremor, ataxia, and dizziness.
When placed in the induction chamber, most nonpremedi-
cated mice (that is, the sevoflurane monoanesthesia group) 
showed behaviors including defecation, urinating, shaking the 
head or limbs, jumping, and locomotion (Table 1). These behav-
iors were less frequent after S-ketamine premedication and were 
nearly totally absent after fentanyl–midazolam premedication. 
One transmitter-implanted mouse died after S-ketamine pre-
medication when the animal was exposed to sevoflurane in the 
induction chamber; this animal was replaced.
Table 1. Behaviors of mice (n = 8 per protocol) during induction of anesthesia with sevoflurane.
Anesthesia
% of animals showing
Locomotion with or  
without ataxia Jumping
Shaking head or  
limbs or both Urination Defecation Apnea or death
FMS 12.5 0 0 0 0 0
KS 100 0 0 37.5 0 12.5
S 100 50 100 100 62.5 0
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recovery phases and lack of motor response to noxious 
stimuli. Subcutaneous injection of fentanyl–midazolam prior 
to sevoflurane inhalant anesthesia induced a gas-saving effect 
and had the advantage of inducing immediate sedation and 
preventing aversive reactions as well as extensive move-
ments at the time of induction with sevoflurane. Injection 
of S-ketamine, the S(+)-enantiomer of ketamine, initially 
induced behavioral aberrations suggestive of excitation but 
attenuated aversive behaviors when mice were exposed to 
sevoflurane. In contrast, when sevoflurane anesthesia was 
induced without premedication, mice responded with def-
ecation, urination, and locomotion including jumping and 
abnormal stationary movements. Compared with sevoflurane 
monoanesthesia, both premedication regimens shortened 
Compared with baseline values, core body temperature in-
creased significantly during the first 12 h after anesthesia with 
KS anesthesia (P = 0.005) and sevoflurane monoanesthesia 
(P = 0.0005) but not after FMS anesthesia (Figure 5). Core body 
temperature was significantly higher after sevoflurane monoan-
esthesia compared with KS and FMS (S compared with FMS, 
P = 0.0005; S compared with KS, P = 0.006).
Locomotor activity and body weight were unchanged in 
all groups after anesthesia relative to baseline values before 
anesthesia.
Discussion
All 3 protocols tested provided a reliable 50-min period 
of anesthesia in laboratory mice, with short induction and 
Figure 3. Mean (n = 8 mice; bar, 1 SD) heart rate, core body temperature, and respiratory rate after premedication in the home cage, in the induc-
tion chamber, and during 50-min sevoflurane anesthesia while mice breathed spontaneously and lay in dorsal recumbency on the warming mat. 
Dashed lines indicate mean baseline values (measured before anesthesia) at the same time of day in conscious mice. The baseline respiratory rate 
was established by counting the movement of the thorax wall in resting mice before anesthesia.
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the time required to reach immobilization after exposure to 
sevoflurane; this effect was most pronounced with fenta-
nyl–midazolam.
During anesthesia, while mice were warmed by a water-filled 
mat, core body temperature and heart rate were depressed 
compared with baseline values obtained at the time of day but 
before anesthesia. Both premedications intensified these ef-
fects, but all values during all 3 protocols remained within the 
ranges considered to be normal for mice. The most important 
adverse side effect that occurred during anesthesia was marked 
respiratory depression, as indicated by respiratory rates that 
were far below those of normal resting mice. This respiratory 
depression was accompanied by pronounced hypoxia, hyper-
capnia, and acidosis, all of which increased with time during 
anesthesia. Such changes in acid–base balance and blood gas-
ses are well-known side effects of inhalant as well as injectable 
anesthesia.3,6,46 The degree of respiratory depression was nearly 
equal among all protocols, but apnea, tachypnea, and cardiac 
arrhythmia occurred with KS anesthesia, and 2 mice in this 
group died.
During the first 12 h after anesthesia, heart rate increased 
in all protocols; this increase was most pronounced during 
sevoflurane monoanesthesia and least apparent during the 
FMS protocol. Core body temperature was increased at 12 h 
after sevoflurane monoanesthesia and to a lesser extent after 
KS anesthesia. Because locomotor activity was unchanged after 
anesthesia regardless of protocol, physical activity is unlikely 
to be the reason for these effects. Postanesthetic measurements, 
including monitoring of body weight, indicated that all 3 proto-
cols had only a short-term effect on the physiology and general 
condition of the mice.
The minimal alveolar concentration of sevoflurane was deter-
mined according to standard principles,41 including generally 
accepted adaptations for the particular species-specific condi-
tions of mice.23,42,43 These modifications mainly concern the fact 
that constant-rate infusions and mechanical ventilation are not 
performed during determination of minimal alveolar concentra-
tion in mice. Furthermore, measurements of minimal alveolar 
concentration in mice were based on the inspired concentration 
of the inhalant, instead of on the end-tidal value, as is typical 
for larger animal species. In addition to the common single 
noxious stimulus induced by pinching the tail of the mouse,7 
we applied 2 other noxious stimuli. The hindlimb withdrawal 
reflex has been shown to be useful for estimating depth of an-
esthesia in mice.24 Because applying a clamp between the toes 
was described as useful during the determination of minimal 
alveolar concentration of isoflurane in mice,14 we incorporated 
this stimulus in the form of pinching the interdigital webbing 
of the paw (pedal withdrawal reflex) in a reproducible man-
ner. As a third noxious stimulus, the abdominal skin pinch 
reflex was applied as described earlier.1 For determination of 
the minimal alveolar concentration of sevoflurane, we applied 
these 3 noxious stimuli only once at a predefined time point of 
inhalant anesthesia to standardize the experimental conditions 
in regard to sevoflurane concentration and the single injection 
of fentanyl–midazolam or S-ketamine, with a view to deter-
mining the pharmacokinetics of the injected agents. Therefore, 
minimal alveolar concentration was determined at 12 min of 
sevoflurane anesthesia, which is congruent with 17 to 19 min 
after subcutaneous injection of the premedication.
The minimal alveolar concentration determined for sevoflu-
rane monoanesthesia (3.3%) for the female C57BL/6J mice 
we tested here was similar to values in from the literature.6,29 
Analgesic substances are known to reduce the minimal alveo-
Figure 4. Mean (n = 8 mice; bar, 1 SD) acid–base balance (pH), pCO2, 
and pO2 in arterial blood after 10, 30, and 50 min of sevoflurane 
anesthesia. Dotted lines indicate baseline levels established from 
HanIbm:NMRI mice in a previous study.1 Dashed lines indicate pub-
lished values from conscious C57BL/6J mice.24
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ing heart rate, blood pressure, or respiration in response to a 
substantially noxious stimulus (for example, skin incision), we 
cannot claim definitively that surgical tolerance was achieved in 
the current study. However, motor reflex responses to noxious 
stimuli were suppressed in all mice for the entire duration of 
anesthesia (that is, 50 min).
Shortly (within approximately 2 min) after injection with 
fentanyl–midazolam, all mice exhibited reduced physical ac-
tivity and a sleep-like posture, likely due to the sedative effect 
of these agents. In contrast, injection of S-ketamine gave rise 
to muscle tremors and ataxia. The spike (up to 800 bpm) in 
heart rate that we noted in the early phase of induction dur-
ing sevoflurane monoanesthesia may be a normal reaction to 
removal of the mouse from its cage and placing it in a foreign 
environment (that is, induction chamber). The markedly lower 
heart rate during the induction phase of the FMS protocol sug-
gests bradycardia due to fentanyl but also indicates the potential 
benefits of sedation, through stress reduction, during the initial 
phase of anesthesia.
During the 50-min anesthesia, mice anesthetized with FMS 
and KS displayed lower heart rate and core body temperature 
than did those anesthetized with S alone. This result can be 
explained by the known influences of fentanyl and ketamine 
lar concentration during inhalant anesthesia in many animal 
species.12,51 In humans, both fentanyl and midazolam induce a 
gas-saving effect when combined with volatile anesthetics.21,31,39 
In the current study, applying 0.04 mg/kg fentanyl in combina-
tion with 4 mg/kg midazolam as a subcutaneous bolus injection 
prior to anesthesia reduced the requirement for sevoflurane 
gas by one third. A similar gas-saving effect with isoflurane 
has been described for ketamine in dogs,40 but combination 
of S-ketamine with sevoflurane did not have this effect in our 
mice. The most probable explanation for this lack is that we 
could not administer S-ketamine as a target-controlled intra-
venous infusion (as is possible in large animals and humans) 
but rather as a single subcutaneous bolus injection. Therefore, 
from a pharmacokinetic viewpoint, the effects of S-ketamine 
might already have been decreasing when we determined the 
minimal alveolar concentration (that is, at 17 to 19 min after 
subcutaneous injection of 30 mg/kg S-ketamine).36
After standardization of the dosages by establishing minimal 
alveolar concentrations, we then compared the 3 protocols at 
dosages of sevoflurane representing 1.5 times the minimal al-
veolar concentrations. At this dosage, it is generally postulated 
that 99.9% of animals will not react to noxious stimuli,11,13 that 
is, that the animals have reached surgical tolerance. However, 
because we did not confirm analgesia by, for example, measur-
Figure 5. Mean (n = 8 mice; bar, 1 SD) postanesthetic measurements of the effects of 3 anesthesia protocols on heart rate and core body tempera-
ture. Delta (Δ) values represent deviations from baseline values (established prior to anesthesia) during the corresponding 12-h day and night 
periods. *, P ≤ 0.05 compared with baseline values and between protocols.
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ity of side effects such as apnea, arrhythmia (including fatal 
abnormalities), and excessive excitation.
In conclusion, premedication with subcutaneous injection of 
fentanyl in combination with midazolam improved standard 
sevoflurane monoanesthesia of mice in our laboratory setting. 
Advantages included a short and quiet induction phase and de-
creased negative postanesthetic side effects on heart rate and core 
body temperature. A gas-saving effect was evident in the FMS 
treatment, corroborating the analgesic potential of the opioid 
component (fentanyl) in this modular anesthesia protocol.
Although all 3 protocols used here may be useful for an-
esthesia in mice, the combination of injection anesthesia with 
inhalation anesthesia could be superior to the widely used 
standard inhalation monoanesthesia, provided that appropriate 
drugs are combined and dosages are adapted to the require-
ments of the specific animals and laboratory. However, the 
choice of a specific anesthetic regimen should always be based 
on careful deliberation, considering arguments of animal wel-
fare, feasibility, and any potential interference with the research 
project for which the anesthesia is required.
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